Inclusion Criteria:

- Unresectable or metastatic, histologically confirmed adenocarcinoma of the stomach,
gastro-oesophageal junction or lower third of the oesophagus with measurable disease
on CT scanning (see RECIST Criteria, Appendix C of the protocol for definition of
measureable disease).

- No previous treatment for advanced disease (previous adjuvant/neo-adjuvant treatment
acceptable if >12 months previously).

- Absence of serious concomitant illness (i.e. MI within previous 6 months),
uncontrolled angina, uncontrolled hypertension, severe COPD (>3 admissions for
infective exacerbation in past 12 months) etc.

- ECOG performance status ≤ 2.

- Age ≥ to 18.

- Life expectancy ≥ 3 months

- Adequate renal, hepatic and bone marrow function

- Creatinine clearance ≥ 50 ml/min as calculated using the Cockcroft and Gault formula
(see Appendix L).

- Liver function tests:

Bilirubin ≤ 1.0 x ULN, AST ≤ 1.5 x ULN, ALT ≤ 1.5 x ULN,Haemoglobin > 10.0 g/dl, Absolute
neutrophil count >1.5 x 109 /L, Platelet count > 100 x109/L.

•Before randomisation, written informed consent must be given according to ICH/GCP, and
national/local regulations.

Exclusion Criteria:

- Symptoms or signs of peripheral neuropathy.

- Patients known to have second or third degree heart block.

- Previous or concurrent malignancy, with the exception of basal cell carcinoma of the
skin or in-situ neoplasia of the uterine cervix.

- Known hypersensitivity to taxanes, oxaliplatin, or fluoropyrimidines.

- Pregnant or nursing.

- Female of child-bearing potential, or male partner of female of child bearing
potential not taking adequate contraceptive precautions.

- Any psychological, familial, sociological or geographical condition potentially
hampering compliance with the study protocol and follow-up schedule; those conditions
should be discussed with the patient before registration in the trial